Monitoring Immunotherapy’s Side Effects in Genitourinary Cancers – Curetoday.com
|
Monitoring Immunotherapy’s Side Effects in Genitourinary Cancers
Curetoday.com While immunotherapy agents are generally well-tolerated, it is important that patients with genitourinary cancers know what kind of side effects to look out for, and when they should contact their health care providers about them. While patients may be … |
Business Insider |
Pfizer executives are changing their tune on an approach for a promising new way to treat cancer, and it could be …
Business Insider When a new form of cancer treatment known as cancer immunotherapy first hit the spotlight, it came with a big promise. In the case of Jimmy Carter, the treatment led the former president to a cancer-free life in his 90s. But other patients haven’t had … |
|
Merck, Foundation Medicine to Develop Companion Diagnostics for Immunotherapy
GenomeWeb NEW YORK (GenomeWeb) – Foundation Medicine has inked a collaboration with Merck to develop companion diagnostic tests for use with Merck’s anti-PD-1 immunotherapy drug Keytruda (pembrolizumab). Under the agreement announced today, the … |
Seeking Alpha |
3 Things In Biotech, May 23: Gene Therapy Continues To Promise
Seeking Alpha Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we’re talking about! Here is some more information if you’re curious. Welcome to another edition of “3 Things In … |
Seeking Alpha |
3 Things In Biotech, May 23: Gene Therapy Continues To Promise
Seeking Alpha Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we’re talking about! Here is some more information if you’re curious. Welcome to another edition of “3 Things In … |
PMLiVE |
Bluebird bags breakthrough status for CALD gene therapy
PMLiVE Bluebird Bio has claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – a rare neurological disease mainly affecting young males. The new status – which could result in a speedy review by the US … bluebird’s Lenti-D Gets Breakthrough Therapy Status From FDAZacks.com FDA ‘Breakthrough’ status for tafamidis and Lenti-DThe Pharma Letter |